VANCOUVER, BC – TheNewswire - SEPTEMBER 30, 2025 – AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY) announces that pursuant the to a share purchase agreement (“144 Agreement”) dated for reference February 17, 2025, announced February 18, 2025, it has completed the acquisition of 100% of the issued and outstanding common shares of 1447377 BC Ltd. (“1447377”), a private BC company that owns a 100% interest in the Hardrock LCT Pegmatite Property ...

Group 1 - SciSparc Ltd. announced the approval of a merger with AutoMax Motors Ltd., enhancing its operations into the automotive sector [1][2] - The merger will result in SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with SciSparc shareholders expected to hold approximately 50.01% of the combined company's share capital [2][3] - The merger aligns with SciSparc's long-term strategy to diversify its portfolio and capitalize on the expanding electric vehicle market in Israel [3] Group 2 - SciSparc has provided financial support to AutoMax, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025 [3] - The closing of the merger is subject to customary closing conditions, including approval from the Israeli court [3] - SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with ongoing drug development programs targeting various disorders [4]

Core Viewpoint - SciSparc Ltd. has announced the approval of a strategic merger with AutoMax Motors Ltd., aiming to enhance shareholder value by diversifying into the automotive sector, particularly focusing on the electric vehicle market in Israel [2][3]. Group 1: Merger Details - The merger will involve SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with AutoMax continuing as a wholly-owned subsidiary [2]. - Following the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company's share capital [2]. - The merger is part of a definitive agreement entered into on April 11, 2024, and marks a significant step in expanding SciSparc's operations [2][3]. Group 2: Financial Support and Strategy - SciSparc has previously supported AutoMax's growth with financial assistance, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025 [3]. - The merger aligns with SciSparc's long-term strategy to diversify its portfolio and capitalize on the expanding electric vehicle market in Israel [3]. Group 3: Closing Conditions - The closing of the merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [4]. - Special meetings for AutoMax's shareholders to vote on the merger approval are scheduled for August 28, 2025 [4]. Group 4: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with ongoing drug development programs based on cannabinoid pharmaceuticals [5]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [5].

Company Overview - Blue Bird Corporation is a bus manufacturer that is significantly investing in the electric bus market, indicating a strategic shift towards sustainable transportation solutions [1]. Recent Performance - The company has experienced a positive trend recently, suggesting strong market performance and potential growth opportunities [1].

Sales Performance - BMW's sales stagnated in the second quarter [1] Market Trends - European carmakers are losing ground to local producers in China [1] - China is the world's biggest electric-vehicle market [1]

Financial Performance - SQM reported net income of US$137.5 million or US$0.48 per share for Q1 2025, a significant recovery from a net loss of US$(869.5) million or US$(3.04) per share in Q1 2024 [2][5] - Total revenues for Q1 2025 were US$1,036.6 million, down 4.4% from US$1,084.5 million in Q1 2024 [3][5] - Gross profit for Q1 2025 was US$304.7 million, representing 29.4% of revenues, compared to US$368.5 million or 34.0% of revenues in Q1 2024 [3] Market Dynamics - Lithium sales volumes increased approximately 27% year-on-year, driven by strong demand from the electric vehicle market, particularly in China, and energy storage systems [4] - Despite stable average prices in Q1 2025, lower prices have been observed recently due to an oversupplied market, leading to expectations of lower realized prices in Q2 2025 [4] - The iodine business is performing well, with steady market growth and upward pressure on prices, while global supply remains limited [4] Production and Capacity - The commissioning of the Mount Holland refinery plant is on track to deliver its first product in the upcoming months, with ongoing sales of spodumene concentrate [4] - SQM aims to reach a total capacity of 240,000 metric tons of lithium carbonate and 100,000 metric tons of lithium hydroxide in Chile [4] - Construction of a seawater pipeline is progressing, which will be crucial for unlocking additional production capacity in the future [4]

Group 1 - The company Blue Bird Corporation (NASDAQ: BLBD) is highlighted as a promising investment in the electric bus sector despite general caution in the electric vehicle market [1] - Management of Blue Bird Corporation has demonstrated strong capabilities, contributing to positive sentiment around the company's future prospects [1] Group 2 - Crude Value Insights provides an investment service focused on oil and natural gas, emphasizing cash flow and the potential for value and growth in these sectors [1] - Subscribers to Crude Value Insights gain access to a stock model account, detailed cash flow analyses of exploration and production firms, and live discussions about the sector [2]

Core Insights - Tesla's dominance in California's electric vehicle market is declining, with a 15.1% drop in registrations in early 2025, marking the steepest quarterly loss in over a year, despite an overall increase in new car registrations by 8.3% year over year [1][2] - Tesla's market share in California's electric vehicle sector fell from 55.5% to 43.9% between Q1 2024 and Q1 2025, indicating increased competition and an aging product lineup [2] - The company's first-quarter delivery numbers were 13% lower than the same period last year, representing the worst quarter since early 2022, and Tesla's stock has decreased by 35% year-to-date [6] Market Dynamics - California remains a crucial market for Tesla, being the largest EV market in the US and the company's birthplace, but the relationship between Tesla and the state has deteriorated in recent years [3] - Elon Musk's relocation of Tesla's headquarters to Texas in 2021 and his alignment with right-wing figures have led to public clashes with California's Democratic leaders, contributing to a negative perception of the company in its home state [4] - Demonstrations against Musk's political involvement have increased, with Tesla vehicles making up 1.4% of all trade-ins in California, a significant rise from 0.4% a year earlier, indicating changing consumer sentiment [5]

Core Viewpoint - Stocks priced under $10 offer an attractive entry point for investors looking to diversify their portfolios and maximize growth potential without significant capital outlay [1] Group 1: Ford Motor Company - Ford Motor Company is currently trading at $9.98 with a dividend yield of 6.02% and a P/E ratio of 6.83, indicating strong value [2][3] - The company reported record revenue of $185 billion for the full year of 2024 and has a positive outlook for 2025, with significant investments in electric vehicle (EV) infrastructure totaling up to $50 billion by 2026 [3] - Ford aims to achieve 2 million annual EV sales by 2026 while maintaining its internal combustion engine vehicle business [3] Group 2: Nokia Oyj - Nokia Oyj is trading at $5.14 with a dividend yield of 1.55% and a P/E ratio of 20.58, positioning it as a key player in telecommunications [5] - The company exceeded Q4 2024 earnings expectations and projects a Comparable Operating Profit between $2.1 billion and $2.7 billion for 2025, alongside strong free cash flow [6] - Nokia's leadership in 5G infrastructure and expansion into high-growth markets like data center networking enhances its revenue diversification [7] Group 3: Goodyear Tire & Rubber Company - Goodyear is currently priced at $9.67 with a P/E ratio of 40.29, indicating potential undervaluation [8][9] - The company reported a full-year 2024 segment operating income of $1.318 billion, reflecting a $350 million year-over-year increase, driven by its "Goodyear Forward" transformation plan [11] - Goodyear aims to achieve $1.5 billion in annual run-rate benefits by the end of 2025 through cost reductions and margin expansion [10] Group 4: Standard Lithium Ltd. - Standard Lithium is trading at $1.23 with a P/E ratio of 2.08, representing a high-risk, high-reward investment opportunity in the EV battery supply chain [12] - The company focuses on innovative Direct Lithium Extraction technology and has received a conditional $225 million grant from the U.S. Department of Energy for its South West Arkansas Project [14] - Standard Lithium's projects in Arkansas position it well to meet the surging demand for lithium in EV batteries [13] Group 5: Mereo BioPharma Group - Mereo BioPharma is priced at $2.45 and focuses on developing drug candidates for rare diseases, presenting a high-risk, high-reward investment opportunity [15] - The company's pipeline includes late-stage candidates Setrusumab and Alvelestat, with Setrusumab receiving Breakthrough Therapy Designation from the U.S. FDA [16] - Mereo has a cash runway extending into 2027, providing financial stability for its clinical programs [17] Group 6: Investment Opportunities - The five identified companies, all priced under $10, present compelling investment opportunities for Q2 2025, with established firms like Ford and Goodyear offering potential value and dividends, while Nokia, Standard Lithium, and Mereo BioPharma represent higher-risk, higher-reward prospects [18]